HIA
KYMR icon

HFM Investment Advisors’s Kymera Therapeutics KYMR Stock Holding History

HFM Investment Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230 Hold
2
– – ﹤0.01% 1165
2026
Q1 		$167 Hold
2
– – ﹤0.01% 1036
2025
Q4 		$156 Buy
2
+1
+100% +$68 ﹤0.01% 1091
2025
Q3 		$57 Buy
+1
New +$45 ﹤0.01% 1209

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

HFM Investment Advisors's KYMR Position: Q2 2026 in Review

HFM Investment Advisors held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 2 shares worth $230. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

HFM Investment Advisors first reported a position in KYMR in Q3 2025 and has held it in 4 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • HFM Investment Advisors held 2 shares of Kymera Therapeutics worth $230 as of Q2 2026.
  • HFM Investment Advisors left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #1165 holding.
  • HFM Investment Advisors first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.